Figure 1.

Temozolomide treatment induces T-cell infiltration into transplanted Melan-ret tumors in a CXCR3-dependent manner. (A-G) C57/BL6 wild type (WT) and Cxcr3^−/− mice were injected subcutaneously in each flank with 10⁶ Melan-ret cells and treated with either 2 mg Temozolomide (TMZ) or vehicle [dimethyl sulfoxide (DMSO)] daily for 3 days once tumors became palpable. Tumors were dissociated and analysed as indicated. (A) qRT-PCR analysis of the gene expression of CD3 and CD8 in transplanted tumors at various time points post- treatment. (B) Flow cytometry analysis of CD4⁺ and CD8⁺ T cells in transplanted tumors at various time points post-treatment. (C) Gene expression of CXCL9 and CXCL10 in transplanted tumors at various time points post-treatment. (D) ELISA analysis of CXCL9 and CXCL10 protein levels in transplanted tumors at various time points post-treatment. (E) Gene expression of CD3, CD4 and CD8 in transplanted Melan-ret tumors from WT and Cxcr3^−/− mice at various time points posttreatment. (F) Flow cytometry analysis for CD3⁺ T cells in transplanted Melan-ret tumors from WT and Cxcr3^−/− mice at day 7 after treatment. (G) Gene expression of CXCL9, CXCL10 and IFNγ in Melan-ret tumors from WT and Cxcr3^−/− mice at various time points post-treatment. Data from panels: (A and C) are pooled from 2 independent experiments with 4-5 mice per group in each experiment (n = 6-8/group); (B and D) consist of 5-7 mice per group; (E-G) are pooled from 2 independent experiments with 3-4 mice per group in each experiment (n = 6-8/group). Bars represent mean ± SD. Statistical analyses were performed using one-way ANOVA test with Bonferroni's post-test analysis; *p<0.05, **p<0.01.